“Through this alliance, the Osaka International Cancer Institute will gain access to novel oncology and hematology treatments in development, allowing Parexel and the Institute to make a strong contribution to clinical trials and the advancement of new cancer treatments,” a Parexel spokesperson told Outsourcing-Pharma.com.
Additionally, the alliance provides local and global sponsors with increased access to patients, which the company said will enable better recruitment for clinical trials.
Parexel – which was acquired in June by a private equity firm – has been operating in Japan since 1995. The company has more than 1,300 employees based in Tokyo, Kobe, and Osaka.
The Osaka International Cancer Institute is made up of a hospital division, research division, and cancer control center. It provides various treatment options, including surgery, chemotherapy, radiotherapy, and immunotherapy treatments.
“Oncology is the largest therapeutic area in clinical trials today,” the spokesperson added. “This alliance is an important step forward in advancing the development of new therapies in this difficult disease.”
Parexel did not provide any comment on the duration of the alliance.